Document:

January 15, 2009 8K Exhibit 4.15

                                                                       Exhibit 4.15 

COMMON STOCK WARRANT

NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION OF THIS WARRANT OR THE
SHARES FOR WHICH THIS WARRANT IS EXERCISABLE MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144
UNDER SAID ACT OR WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL
FOR THE HOLDER, SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT OR
RECEIPT OF A NO-ACTION LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION.

WARRANT TO PURCHASE SHARES OF COMMON STOCK

	
Dated:
	
  January 27, 2009

THIS CERTIFIES THAT, for value received,  ("Holder") is
entitled to subscribe for and purchase that number of shares as set forth in Section 1 of the fully paid and nonassessable Common Stock
(the "Shares" or the "Common Stock") of FAVRILLE, INC., a Delaware corporation (the "Company"), at the
Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, the
term "Common Stock" shall mean the Company's presently authorized Common Stock. 

This Warrant is being issued pursuant to that certain Creditor Plan dated November 8, 2008 by and among the
Company, mymedicalrecords.com, Inc., a Delaware corporation ("MMR"), and Kershaw, Mackie & Co., (the "Creditor
Plan").

1.          Warrant Price; Grant.  The
"Warrant Price" per share shall initially be $0.12, and this Warrant shall be exercisable for  () shares of Common Stock (the "Grant"), subject to adjustment as provided in
Section 7 below. 

2.          Conditions to Exercise.  The
purchase right represented by the Grant may be exercised at any time, or from time to time, in whole or in part during the term
commencing on the date hereof and ending at 5:00 P.M. Eastern Standard time on January 26, 2014. 

3.          Method of Exercise; Payment; Issuance of
Shares; Issuance of New Warrant.

(a)        Cash Exercise. Subject to Sections 1 and 2
hereof, the purchase right represented by this Warrant may be exercised by the Holder hereof, in whole or in part, by the surrender of this
Warrant (with a duly executed Notice of Exercise in the form attached hereto) at the principal office of the Company (as set forth in
Section 17 below) and by payment to the Company, by check, of an amount equal to the then applicable Warrant Price per share
multiplied by the number of shares then being purchased. In the event of any exercise of the rights represented by this Warrant, certificates for
the shares of stock so purchased shall be in the name of, and delivered to, the Holder hereof, or as such Holder may direct (subject to the
terms of transfer contained herein and upon payment by such Holder hereof of any applicable transfer taxes). Such delivery shall be made
within 10 days after exercise of the Warrant and at the Company's expense and, unless this Warrant has been fully exercised or expired, a new
Warrant having terms and conditions substantially similar to this Warrant and representing the portion of the Shares, if any, with respect to

which this Warrant shall not have been exercised, shall also be issued to the Holder hereof within 10 days after exercise of the
Warrant.

(b)        Net Issue Exercise. In lieu of exercising this
Warrant pursuant to Section 3(a), Holder may elect to receive shares equal to the value of this Warrant (or of any portion thereof
remaining unexercised) by surrender of this Warrant at the principal office of the Company together with notice of such election, in which event
the Company shall issue to Holder the number of shares of the Company's Common Stock computed using the following formula:

X = Y (A-B)  

          A 

Where X = the number of shares of Common Stock to be issued to Holder.

Y = the number of shares of Common Stock purchasable under this Warrant (at the date of such
calculation).

A = the Fair Market Value of one share of the Company's Common Stock (at the date of such calculation).

B = Warrant Price per share (as adjusted to the date of such calculation).

(c)        Fair Market Value. For purposes of this
Section 3, "Fair Market Value" of one share of the Company's Common Stock shall mean:

(i)         If the Common Stock is traded Over-The-Counter or
on The NASDAQ Stock Market, LLC or on another exchange, the per share Fair Market Value for the Common Stock will be the average of the
closing bid and asked prices of the Common Stock quoted in the Over-The-Counter Market Summary or the closing sales price quoted on any
exchange on which the Common Stock is listed, whichever is applicable, as published in the Western Edition of The Wall Street Journal for the
twenty (20) trading days prior to the date of determination of Fair Market Value; or

(ii)        In any other instance, the per share Fair Market Value for the
Common Stock shall be as determined in good faith by the Company's Board of Directors (the "Board").

In the event of 3(c)(ii) above, the Company's Board of Directors shall prepare a certificate, to be signed by an
authorized officer of the Company, setting forth in reasonable detail the basis for and method of determination of the per share Fair Market
Value of the Common Stock. The Board will also certify to the Holder that this per share Fair Market Value will be applicable to all holders of the
Company's Common Stock that require a fair market value determination as of the same date as Holder.

(d)        Automatic Exercise. To the extent this Warrant is
not previously exercised, it shall be automatically exercised in accordance with Sections 3(b) and 3(c) hereof (even if not
surrendered) immediately before its expiration.

                                           2

(e)No Net Cash Settlement.  Notwithstanding any other provision of this Warrant to the contrary, under no
circumstances will the Company be required to effect any "net-cash settlement" (within the meaning of the Financial Accounting
Standards Board's EITF 00-19, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's
Own Stock) of this Warrant.

 4.          Representations and Warranties of
Holder and Restrictions on Transfer Imposed by the Securities Act of 1933.

(a)        Representations and Warranties by Holder. The
Holder represents and warrants to the Company with respect to this purchase as follows:

(i)         The Holder has substantial experience in evaluating
and investing in private placement transactions of securities of companies similar to the Company so that the Holder is capable of evaluating the
merits and risks of its investment in the Company and has the capacity to protect its interests. The Holder is an "accredited investor"
as that term is defined in Rule 501 promulgated under the Securities Act of 1933, as amended (the "Act").

(ii)        The Holder is acquiring the Warrant and the Shares of
Common Stock issuable upon exercise of the Warrant (collectively the "Securities") for investment for its own account and not with a
view to, or for resale in connection with, any distribution thereof. The Holder understands that the Securities have not been registered under the
Act by reason of a specific exemption from the registration provisions of the Act, which depends upon, among other things, the bona fide nature
of the investment intent as expressed herein. In this connection, the Holder understands that, in the view of the Securities and Exchange
Commission (the "SEC"), the statutory basis for such exemption may be unavailable if this representation was predicated
solely upon a present intention to hold the Securities for the minimum capital gains period specified under tax statutes, for a deferred sale, for or
until an increase or decrease in the market price of the Securities or for a period of one year or any other fixed period in the future.

(iii)       The Holder acknowledges that the Securities must be held
indefinitely unless subsequently registered under the Act or an exemption from such registration is available. The Holder is aware of the
provisions of Rule 144 promulgated under the Act ("Rule 144") which permits limited resale of securities purchased in a
private placement subject to the satisfaction of certain conditions more fully set forth in such rule.

(iv)       The Holder further understands that at the time the Holder wishes
to sell the Securities there may be no public market upon which such a sale may be effected, and that even if such a public market
exists, the Company may not be satisfying the current public information requirements of Rule 144, and that in such event, the
Holder may be precluded from selling the Securities under Rule 144.

(v)        The Holder has had an opportunity to (i) discuss the
Company's and MMR's business, management and financial affairs with the Company and MMR management, (ii) review the Company's and
MMR's operations and facilities to the extent reasonably requested and (iii) ask questions of and receive answers

                                           3

from the Company and MMR
and their management regarding the terms and conditions of the merger of Montana Merger Sub, Inc., a Delaware corporation and a wholly
owned subsidiary of the Company ("Merger Sub"), with and into MMR (the "Merger") pursuant to that certain Agreement
and Plan of Merger and Reorganization dated November 8, 2008 by and among the Company, MMR and Merger Sub (the "Merger
Agreement") and Holder's proposed investment in order to allow Holder to make an informed decision about whether to accept the Shares
in connection with the Creditor Plan.  The Holder understands that all such discussions, as well as the written information issued by the
Company and MMR (including the Merger Agreement) were intended to describe the Merger and the aspects of the Company's and MMR's
business and prospects which they believe to be material but were not necessarily a thorough or exhaustive description. 

(vi)       This Warrant and the Shares issuable upon exercise of this Warrant
(and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in
part without compliance with applicable federal and state securities laws by the transferor and the transferee (including, without limitation,
the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the
Company) and any permitted transferee agrees to be bound by all of the terms and conditions of this Warrant. The Company shall not require
Holder to provide an opinion of counsel if the transfer is to any other affiliate of Holder. Additionally, the Company shall also not require an
opinion of counsel if there is no material question as to the availability of Rule 144.

(b)        Legends. Each certificate representing the
Securities shall be endorsed with the following legend:

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
AND MAY NOT BE TRANSFERRED UNLESS COVERED BY AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT, A
"NO ACTION" LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION WITH RESPECT TO SUCH TRANSFER, A
TRANSFER MEETING THE REQUIREMENTS OF RULE 144 OF THE SECURITIES AND EXCHANGE COMMISSION, OR (IF
REASONABLY REQUIRED BY THE COMPANY) AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER TO THE EFFECT THAT
ANY SUCH TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

The Company need not enter into its stock register a transfer of Securities unless the conditions specified in the
foregoing legend are satisfied. The Company may also instruct its transfer agent not to register the transfer of any of the Shares unless
the conditions specified in the foregoing legend are satisfied.

(c)        Removal of Legend and Transfer Restrictions. The
legend relating to the Act endorsed on a certificate pursuant to paragraph 4(b) of this Warrant and the stop transfer instructions with
respect to the Securities represented by such certificate shall be removed and the Company shall issue a certificate without such legend to the
Holder of the Securities if (i) the Securities are registered under the Act and a prospectus meeting the requirements of Section 10
of the Act is available or (ii) the Holder provides to the Company an opinion of counsel for the Holder reasonably satisfactory to the
Company, or a no-action

                                           4

letter or interpretive opinion of the staff of the SEC reasonably satisfactory to the Company, to the effect that public
sale, transfer or assignment of the Securities may be made without registration and without compliance with any restriction such as
Rule 144.

5.         Assignment. Notwithstanding any other
provision of this Warrant, neither the Company nor the Holder may assign this Warrant without the written consent of the other party hereto. It
shall be a condition to any transfer or exercise of this Warrant that at the time of such transfer or exercise, the Holder shall provide the Company
with a representation in writing that the Holder or transferee is acquiring this Warrant and the shares of Common Stock to be issued upon
exercise, for investment purposes only and not with a view to any sale or distribution, or will provide the Company with a statement of pertinent
facts covering any proposed distribution. As a further condition to any transfer of this Warrant or any or all of the shares of Common Stock
issuable upon exercise of this Warrant, other than a transfer registered under the Act, the Company must have received a legal opinion, in
form and substance satisfactory to the Company and its counsel, reciting the pertinent circumstances surrounding the proposed transfer
and stating that such transfer is exempt from the registration and prospectus delivery requirements of the Act. Each certificate evidencing the
shares issued upon exercise of the Warrant or upon any transfer of the shares (other than a transfer registered under the Act or any subsequent
transfer of shares so registered) shall, at the Company's option, contain a legend in form and substance satisfactory to the Company and
its counsel, restricting the transfer of the shares to sales or other dispositions exempt from the requirements of the Act.  As further condition to
any transfer, the Holder shall surrender this Warrant to the Company and the transferee shall receive and accept a Warrant, of like tenor and
date, executed by the Company.

6.          Stock Fully Paid; Reservation of
Shares.  All Shares which may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be
fully paid and nonassessable, and free from all taxes, liens, and charges with respect to the issue thereof. During the period within which the
rights represented by this Warrant may be exercised, the Company will at all times have authorized, and reserved for issuance upon
exercise of the purchase right evidenced by this Warrant, a sufficient number of shares of its Common Stock to provide for the exercise of the
rights represented by this Warrant.

7.         Certain Adjustments.

(a) Stock Dividends and Splits.  If the Company, at any time while this Warrant is outstanding, (i) pays
a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common
Stock, (ii) subdivides outstanding shares of Common Stock into a larger number of shares, or (iii) combines outstanding shares of Common
Stock into a smaller number of shares, then in each such case the Warrant Price shall be multiplied by a fraction of which the numerator shall be
the number of shares of Common Stock outstanding immediately before such event and of which the denominator shall be the number of
shares of Common Stock outstanding immediately after such event.  Any adjustment made pursuant to clause (i) of this paragraph shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, and any
adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or
combination.

(b) Fundamental Transactions.  If, at any time while this Warrant is outstanding, (i) the Company
effects any merger or consolidation of the Company with or into another individual, limited liability company, partnership, joint venture,
corporation, a trust,  unincorporated organization,  government or any department or agency thereof and any other legal entity (each a
"Person"), (ii) the Company effects any sale of all or

                                           5

substantially all of its assets in one or a series of related transactions, (iii) any
tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock owning
more than 50% of the outstanding shares of Common Stock (not including  any shares of Common Stock held by the Person or Persons making
or affiliated with the Persons making the tender or exchange offer) tender or exchange their shares for other securities, cash or property, or (iv)
the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of
Common Stock covered by Section 7(a) above) (in any such case, a "Fundamental Transaction"), then Holder shall have the right
thereafter to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to
receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of
the number of shares of Common Stock then issuable upon exercise of the Grant (the "Alternate Consideration").  For purposes of
any such exercise, the determination of the Warrant Price shall be appropriately adjusted to apply to such Alternate Consideration based on the
amount of Alternate Consideration issuable on one share of Common Stock in such Fundamental Transaction, and the Company shall
apportion such Warrant Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different
components of the Alternate Consideration.  If holders of Common Stock are given any choice as to the securities, cash or property to be
received in a Fundamental Transaction, then Holder shall be given the same choice as to the Alternate Consideration it receives upon any
exercise of this Warrant following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor
to the Company or surviving entity in such Fundamental Transaction shall issue to Holder a new warrant consistent with the foregoing provisions
and evidencing  Holder's right to purchase the Alternate Consideration for the aggregate Warrant Price upon exercise thereof.

(c)Number of Shares.  Simultaneously with any adjustment to the Warrant Price pursuant to paragraph (a)
of this Section 7, the number of shares of Common Stock that may be purchased upon exercise of this Warrant shall be adjusted
proportionately, so that after such adjustment the aggregate Warrant Price payable hereunder for the increased number of shares of Common
Stock shall be the same as the aggregate Warrant Price in effect immediately prior to such adjustment.

(d)Calculations.  All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th
of a share, as applicable.  The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or
for the account of the Company, and the disposition of any such shares shall be considered an issue or sale of Common Stock.

8.          Notice of Adjustments.
 Whenever any Warrant Price shall be adjusted pursuant to Section 7 hereof, the Company shall prepare a certificate signed by its
chief financial officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which
such adjustment was calculated, and the Warrant Price and number of Shares issuable upon exercise of the Warrant after giving effect to such
adjustment, and shall cause copies of such certificate to be mailed (by certified or registered mail, return receipt required, postage prepaid)
within thirty (30) days of such adjustment to the Holder of this Warrant as set forth in Section 17 hereof.

                                           6

9.        Transferability of Warrant. This Warrant is
transferable on the books of the Company at its principal office by the registered Holder hereof upon surrender of this Warrant properly
endorsed, subject to compliance with Section 5 and applicable federal and state securities laws. The Company shall issue and deliver to
the transferee a new Warrant representing the Warrant so transferred. Upon any partial transfer, the Company will issue and deliver to Holder a
new Warrant with respect to the Warrant not so transferred.

10.        No Fractional Shares.  No fractional share of
Common Stock will be issued in connection with any exercise hereunder, but in lieu of such fractional share the Company shall make a cash
payment therefor upon the basis of the Warrant Price then in effect.

11.        Charges, Taxes and Expenses. Issuance of
certificates for shares of Common Stock upon the exercise of this Warrant shall be made without charge to the Holder for any United States or
state of the United States documentary stamp tax or other incidental expense with respect to the issuance of such certificate, all of which taxes
and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder.

12.        No Stockholder Rights Until Exercise. This Warrant
does not entitle the Holder hereof to any voting rights or other rights as a stockholder of the Company prior to the exercise hereof.

13.        Registry of Warrant. The Company shall maintain a
registry showing the name and address of the registered Holder of this Warrant. This Warrant may be surrendered for exchange or
exercise, in accordance with its terms, at such office or agency of the Company, and the Company and Holder shall be entitled to rely in all
respects, prior to written notice to the contrary, upon such registry.

14.        Loss, Theft, Destruction or Mutilation of Warrant.
Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and, in the
case of loss, theft, or destruction, of indemnity reasonably satisfactory to it, and, if mutilated, upon surrender and cancellation of this Warrant,
the Company will execute and deliver a new Warrant, having terms and conditions substantially identical to this Warrant, in lieu hereof.

15.        Miscellaneous.

(a)        Issue Date.  The provisions of this Warrant
shall be construed and shall be given effect in all respect as if it had been issued and delivered by the Company on the date hereof.

(b)        Successors.  This Warrant shall be binding
upon any successors or assigns of the Company.

(c)        Governing Law.  This Warrant shall be
governed by and construed in accordance with the laws of the State of California.

(d)        Headings.  The headings used in this
Warrant are used for convenience only and are not to be considered in construing or interpreting this Warrant.

(e)        Saturdays, Sundays, Holidays.  If the last or
appointed day for the taking of any action or the expiration of any right required or granted herein shall be a Saturday or a Sunday or shall be a
legal holiday in the State of California, then such action may be taken or such right may be exercised on the next succeeding day
not a legal holiday.

                                           7

16.        No Impairment. The Company shall not by any
action including, without limitation, amending its articles or certificate of incorporation or by-laws, any reorganization, transfer of assets,
consolidation, merger, share exchange dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms of the Warrant or impair the ability of the Holder(s) to realize upon the intended economic value
hereof, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary
or appropriate to protect the rights of the Holder(s) hereof against impairment.

17.        Addresses. Any notice required or permitted
hereunder shall be in writing and shall be mailed by overnight courier, registered or certified mail, return receipt required, and postage pre-paid,
or otherwise delivered by hand or by messenger, addressed as set forth below, or at such other address as the Company or the Holder hereof
shall have furnished to the other party.

	
If to the Company:
	
 
	
Favrille, Inc.

	
 
	
 
	
29341⁄2 Beverly Glen Circle, Suite 702

	
 
	
 
	
Los Angeles, CA 90077

	
 
	
 
	
Attn: Naj Allana

	
 
	
 
	
 

	
If to the Holder:
	
 
	

	
 
	
 
	

	
 
	
 
	

	
 
	
 
	

18.        Modification and Waiver. The Warrant and any
provision hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the Company and the
Holder of the Warrant.

[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

                                           8

IN WITNESS WHEREOF, the Company and Holder have each caused this Warrant to be executed by an officer
thereunto duly authorized.

Dated as of January 27, 2009.

	
FAVRILLE, INC.

	
 

	
By:
	
__________________________
	
 

	
 
	
 
	
 

	
Name:
	
  Tamara A. Seymour
	
 

	
 
	
 
	
 

	
Title:
	
  Chief Financial Officer
	
 

	 
	
 

	
By:
	
__________________________
	
 

	
 
	
 
	
 

	
Name:
	
__________________________
	
 

NOTICE OF EXERCISE

	
TO:
	
 
	
 

	
 
	
 
	
 

	
 
	
 
	
 

1.          The undersigned Warrantholder
("Holder") elects to acquire shares of the Common Stock (the "Common Stock") of Favrille, Inc. (the
"Company"), pursuant to the terms of the Common Stock Warrant dated January 27, 2009 (the "Warrant").

2.          The Holder exercises its rights under the
Warrant as set forth below:

o
         The Holder elects to purchase _________ shares of Common Stock as
provided in Section 3(a) and 3(c) and tenders herewith a check in the amount of $_______ as payment of the Warrant Price.

o
         The Holder elects to net issue exercise the Warrant for shares of
Common Stock as provided in Section 3(b) and 3(c) of the Warrant.

3.          The Holder surrenders the Warrant with this
Notice of Exercise.

4.          The Holder represents that it is acquiring the
aforesaid shares of Common Stock for investment and not with a view to, or for resale in connection with, distribution and that the Holder has no
present intention of distributing or reselling the shares unless in compliance with all applicable federal and state securities laws.

5.          Please issue a certificate representing the
shares of the Common Stock in the name of the Holder or in such other name as is specified below:

	
 
	
Name:
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
Address:
	
 
	
 

	
 
	
 
	
 
	
 

	
 
	
Taxpayer I.D.:
	
 
	
 

	
 
	
 
	
 
	
 

	
By:
	
_______________________________
	
 

	
 
	
 
	
 

	
Name:
	
_______________________________
	
 

	
 
	
 
	
 

	
Title:
	
_______________________________
	
 

	
 
	
 
	
 

	
Date:
	
_______________________________January 27, 2009 8K Exhibit 10.8

                                                                       Exhibit 10.8 

ALLONGE

This Allonge, dated January 27, 2009 (this "Allonge"), is to be physically attached to that certain Promissory Note entitled as
"Second Amended and Restated Promissory Note" in the stated amount of "$1,000,000 or more", dated August 1, 2008 by
and between My MedicalRecords.com, Inc., a Delaware corporation ("Borrower") and The RHL Group, Inc., a California corporation
("Lender") (as amended and modified hereby, the "NOTE"). Reference is also made to that certain Security Agreement,
dated July 31, 2007 by and between Borrower and Lender which secured Borrower's obligations under the NOTE (as amended and modified
hereby, the "Security Agreement").

The purpose of this Allonge is to suspend certain rights (the "SUSPENDED RIGHTS") held by the Lender from the Closing
Date, as that term is defined in that certain Agreement and Plan of Merger and Reorganization dated November 8, 2008 (the "Merger Agreement"), by and among Favrille, Inc., a Delaware corporation ("Favrille"), Montana
Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent and
Borrower, until the earlier of: either (1) the date that Favrille or Borrower repays all amounts outstanding under the "Notes" issued
pursuant to the Creditor Plan (as defined in the Merger Agreement) in the maximum aggregate amount of up to $1,160,000, (2) the date that
Favrille or Borrower deposits into the Escrow Fund (as defined in the Creditor Plan) the maximum amount of cash (up to $1.16 million, which
maximum amount will be confirmed by Favrille to the Company on or before the Closing based upon the terms of the Settlement Agreements (as
defined in the Creditor Plan) executed on or prior to Closing) payable in satisfaction of the "Notes" issued pursuant to the Creditor
Plan; or (3) ten days after the two year anniversary of the Closing Date (the "NEW DUE DATE"). In addition the purpose of the
Allonge is to temporarily affect certain terms of the NOTE and the Security Agreement as more fully set forth herein  (the
"MODIFICATION"). Capitalized terms not otherwise defined herein shall have the meaning ascribed to such terms in the NOTE.

 Other than as stated herein the NOTE and Security Agreement remain unaltered, and in full force and effect.  Only this Allonge shall
expressly or impliedly alter the terms of the NOTE and Security Agreement; no other writing, or document, whether now or in the future signed,
shall alter or modify the terms of the NOTE or the Security Agreement, or the NOTE or Security Agreement itself, except a document entitled as
"Amended Allonge" executed by both the Borrower and the Lender (and no one else), which document, if it exists, shall also be
attached to the NOTE.  A condition precedent to the effectiveness of this Allonge is the passage of a resolution by the Board of Directors of
Borrower to the effect that the NOTE is: (a) in full force and effect; (b) is fully enforceable; (c) no defenses exist as to the NOTE; and (d) the
amount due under the NOTE as of the date of this Allonge is $1,016,145.

The SUSPENDED RIGHTS are as follows:

	Any right of the Lender to declare a Default or an Event of Default (as defined in the NOTE and the Security Agreement) or deliver any notice
thereof to Borrower.
	Any right of the Lender to accelerate the maturity date of the NOTE (whether the Final Maturity Date or the NEW DUE DATE).
	Any right of the Lender to exercise any of the remedies referenced in Section 6.3 of the Security Agreement.
	Any right of the Lender to assign the NOTE, or the proceeds of the NOTE, or otherwise negotiate the NOTE.
	Any right of the Lender to receive payment of the Unpaid Balance of the NOTE as that term is defined in the NOTE, including without
limitation payments for monthly interest and CREDIT CARD ADVANCES under the NOTE.

The MODIFICATIONS are as follows:  

1.The Final Maturity Date shall now be the NEW DUE DATE.

2.Notwithstanding any other provisions of the NOTE and the Security Agreement
Lender hereby agrees and acknowledges that the Unpaid Balance under the NOTE is expressly subordinated in right of payment to the prior
payment of the Indebtedness.  The Indebtedness shall be deemed paid when the entire amount due to retire the Indebtedness is deposited into
the Escrow Fund. "Indebtedness" shall mean the principal amount due under the Notes (an amount that shall range from $800,000 to
$1,160,000, as defined in the Creditor Plan) to be issued to the Creditors (as defined in the Creditor Plan) pursuant to the Creditor Plan and any
costs and expenses payable under the Notes.

3.Lender hereby subordinates to the holders of Indebtedness any security interest or lien that Lender may have in all Collateral (as
defined in the Security Agreement). Notwithstanding the respective dates of attachment or perfection of the security interest of Lender and the
security interest of the holders of Indebtedness, the security interest of the holders of Indebtedness in the Collateral, shall be prior to the security
interest, if any, of Lender until the Company shall have paid the Indebtedness in full to the Escrow Agent.

4.Lender hereby expressly waives, both now and in the future, any Default or Event of Default under the NOTE and the Security
Agreement that arises from or is related to the Closing (as that term is defined in the Merger Agreement) and the consummation of the
transactions described in the Merger Agreement.

5.Each of the representations, warranties and covenants included in the NOTE and Security Agreement are hereby qualified and/or
waived as necessary to address the purpose and effect of the SUSPENDED RIGHTS and the MODIFICATIONS set forth in this Allonge to the
extent it is readily apparent that such qualification and/or waiver is necessary to give effect to the terms and provisions of this Allonge.

                                           2

6.This Allonge is being executed in connection with the consummation of the
transactions described in the Merger Agreement and the documents signed on the Effective Time as that term is defined in the Merger
Agreement, but shall not be attached to the NOTE or effective unless and until the Closing Date (as that term is defined in the Merger
Agreement) has successfully passed.

7.Upon the Closing Date having successfully passed the Lender shall deliver the NOTE (with this Allonge affixed) and the Security
Agreement to the Escrow Agent.  Said Escrow Agent shall hold said documents until the Company shall have paid the Indebtedness in full to the
Escrow Agent, including if applicable through deposit of the funds into the Escrow Fund.  Upon the payment of the Indebtedness in full to the
Escrow Agent: (a) the Escrow Agent will be instructed by both the Company and the Lender to return the NOTE, Allonge and Security Agreement
to the Lender, who shall then have the power to detach the Allonge from the NOTE; (b) the Allonge shall have no further power and effect;  (c)
any security interest, if any, shall be deemed unenforceable; and (d) Lender shall be deemed to be, and is, restored to the position that it held
immediately prior to the execution of this Allonge.  The Escrow Agent, in returning the NOTE, the Allonge affixed, and the Security Agreement
only needs to determine whether or not the Borrower or Favrille have deposited funds into the Escrow Fund sufficient to pay the Indebtedness in
full; it is not required to get any other, or further, assurance or understanding from any Party whatsoever.

If the Indebtedness has not otherwise been fully paid by the NEW DUE DATE (as provided just above), then upon the passage of the NEW
DUE DATE this Allonge shall become ineffective, and the Security Agreement, NOTE, and Allonge shall be returned to the Borrower;
who may then detach the Allonge from the NOTE.

"BORROWER"

   MyMedicalRecords.com, Inc., 

a Delaware corporation ("Debtor")

Name: Naj Allana

Title: CFO

Signature: /s/ Naj Allana

"LENDER"

   The RHL Group, Inc., 

 a California corporation ("Secured Party") 

Name: Robert H. Lorsch

Title: CEO, Chairman

Signature: /s/ Robert H. Lorsch

                                           3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}]]